HHTM's mission is to bridge the knowledge gaps in treating hearing loss by providing timely information and lively insights to anyone who cares about hearing loss. Our contributors and readers are drawn from many sectors of the hearing field, including practitioners, researchers, manufacturers, educators, and, importantly, consumers with hearing loss and those who love them.
Featured image for “Tuned Raises $2.5M Seed Round with Aim to ‘Radically Upend Status Quo’ in Hearing Care”
Sep. 19, 2022

Tuned Raises $2.5M Seed Round with Aim to ‘Radically Upend Status Quo’ in Hearing Care

HHTM
NEW YORK CITY, NEW YORK — Tuned, a hearing health company focused on providing hearing care for all, today announced that it raised $2.5 million in seed funding, led by Idealab NY and Elements Health Ventures. Following successful pilots with companies such as RetailBound and Mishe, the injection of new capital will be used to scale employer adoption and bring comprehensive hearing wellness to
Featured image for “Akouos Receives FDA Clearance of its IND Application for Gene Therapy Hearing Loss Treatment, AK-OTOF”
Sep. 19, 2022

Akouos Receives FDA Clearance of its IND Application for Gene Therapy Hearing Loss Treatment, AK-OTOF

HHTM
BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human, pediatric clinical trial of AK-OTOF,
Featured image for “NIH Genomics Researchers Identify  Unique Set of Proteins that Restore Hearing in Zebrafish”
Sep. 18, 2022

NIH Genomics Researchers Identify Unique Set of Proteins that Restore Hearing in Zebrafish

HHTM
WASHINGTON, D.C. — National Institutes of Health researchers have discovered a specific network of proteins that is necessary to restore hearing in zebrafish through cell regeneration. The study, led by investigators at the National Human Genome Research Institute (NHGRI), may inform the development of treatments for hearing loss in humans. The findings were published in Cell Genomics. Although hair cell loss cannot
Featured image for “First Patient Enrolled in Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation”
Sep. 16, 2022

First Patient Enrolled in Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

HHTM
MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced that the first patient has been enrolled in its proof-of-concept clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation. At the beginning of 2021,
Featured image for “2022 EUHA Congress to Take Place on October 12th”
Sep. 16, 2022

2022 EUHA Congress to Take Place on October 12th

HHTM
FRANKFURT/MAINZ — The 66th International Congress of Hearing Aid Acousticians (EUHA) and the accompanying Industry Exhibition will provide insights into innovations in the field of hearing on October 12, 2022. More than 25 top-class expert lectures, five tutorials, and four forward-looking Future  Friday lectures will be on offer for participants. In addition, they will debut the EUHA  Science Symposium on
Featured image for “Hearing Aid Alternatives: Inexpensive SMARTO Device Offers Appealing Features for Patients and Professionals”
Sep. 14, 2022

Hearing Aid Alternatives: Inexpensive SMARTO Device Offers Appealing Features for Patients and Professionals

HHTM
Battered and bruised, stuck in a cabinet for many months, then ready for action at a moment’s notice — think of all the loved ones, spouses and companions who shouted, “Can you hear me now?” into its bulbous black microphone, those ubiquitous pocket amplifiers had a great run. If you haven’t already, now might be a good time to ditch
Featured image for “Sony and WS Audiology Announce Partnership on OTC Self-Fitting Hearing Aid Business”
Sep. 13, 2022

Sony and WS Audiology Announce Partnership on OTC Self-Fitting Hearing Aid Business

HHTM
TOKYO AND LYNGE, DENMARK — Sony Corporation and WS Audiology Denmark A/S have entered into a partnership agreement and various ancillary agreements with the aim of jointly developing and supplying new products and services in the over-the-counter self-fitting hearing aid market, beginning with the United States. Through the partnership, Sony and WSA will combine their respective technological and medical expertise to create
Featured image for “Animal Audiology: A Discussion with FETCHLAB™ Akron Director, Dr. Kristine Sontrsom Malowski”
Sep. 13, 2022

Animal Audiology: A Discussion with FETCHLAB™ Akron Director, Dr. Kristine Sontrsom Malowski

HHTM
How do you test a dog’s hearing and what exactly is Animal Audiology? This week, Heather Malyuk is joined by Dr. Kristine Sontrsom Malowski, Director of the Akron FETCHLAB™ at the University of Akron. They discuss all things animal audiology and the fascinating work being done by Dr. Sonstrom Malowski’s at the Akron FETCHLAB™ to evaluate the hearing status in
Featured image for “Reading Lips Through Masks? New ‘Remarkably Accurate’ Technology Could Help Create Next Gen Hearing Aids”
Sep. 12, 2022

Reading Lips Through Masks? New ‘Remarkably Accurate’ Technology Could Help Create Next Gen Hearing Aids

HHTM
A new system capable of reading lips with remarkable accuracy even when speakers are wearing face masks could help create a new generation of hearing aids. An international team of engineers and computing scientists developed the technology, which pairs radio-frequency sensing with artificial intelligence for the first time to identify lip movements. The system, when integrated with conventional hearing aid
Featured image for “Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT from the European Medicine Agency”
Sep. 12, 2022

Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT from the European Medicine Agency

HHTM
MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage  biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion on Sensorion’s application for Orphan Drug Designation (ODD) for its